Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jul;88(1):25-9.
doi: 10.1136/heart.88.1.25.

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

P H Whincup  1 , J R Emberson, L Lennon, M Walker, O Papacosta, A Thomson
Affiliations

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

P H Whincup et al. Heart. 2002 Jul.

Abstract

Objective: To determine the prevalence and correlates of lipid lowering drug use among older British men with established coronary heart disease (CHD).

Design: Cross sectional survey within a cohort study (British regional heart study) carried out at 20 years of follow up in 1998-2000.

Setting: General practices in 24 British towns.

Participants: 3689 men aged 60-75 years (response rate 76%).

Main outcome measures: Diagnoses of myocardial infarction and angina based on detailed review of general practice records. Lipid lowering drug use and blood cholesterol concentrations ascertained at 20 year follow up examination.

Results: Among 286 men with definite myocardial infarction, 102 (36%) were taking a lipid lowering drug (93 (33%) a statin); among 360 men with definite angina without myocardial infarction, 84 (23%) were taking a lipid lowering drug (78 (21%) a statin). Most men with documented CHD who were not receiving a lipid lowering drug had a total cholesterol concentration of 5.0 mmol/l or more (87% of those with myocardial infarction, 82% with angina). Fewer than half of men with CHD receiving a statin had a total cholesterol concentration below 5.0 mmol/l (45% of those with myocardial infarction and 47% of those with angina). Only one third of the men taking a statin were receiving trial validated dosages. Among men with CHD, a history of revascularisation, more recent diagnosis, and younger age at diagnosis were associated with a higher probability of receiving lipid lowering drug treatment.

Conclusion: Among patients with established CHD, the prevalence of lipid lowering drug use remains low and statin regimens suboptimal. Major improvements in secondary prevention are essential if the benefits of statins are to be realised.

PubMed Disclaimer

References

    1. Scandinavian Simvastatin Survival Study Group. Randomized controlled trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383–9. - PubMed
    1. Sacks FM, Pfeiffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9. - PubMed
    1. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57. - PubMed
    1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301–7. - PubMed
    1. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. JAMA 1998;279:1615–22. - PubMed

Publication types